Wednesday, 28 October, 2020

Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60

Sixty dollar experimental vaccine rolled out in east Chinese city Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60 (RM 249)
Gustavo Carr | 18 October, 2020, 13:48

Having refused permission earlier, the Drugs Controller General of India (DCGI) has now allowed Dr Reddy's to conduct phase 2/3 clinical human trials of Russia's Sputnik V vaccine candidate.

Sputnik V vaccine, developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, was registered by Russia's Ministry of Health of Russian Federation on August 11 to become the world's first registered vaccine against COVID-19. The "multi-center and randomized controlled study" will be conducted by Dr Reddy's Laboratories, a Hyderabad-based pharmaceutical giant.

According to the Times of India, frontline health and sanitation workers, police officials and elderly people with co-morbidities will get the vaccine on priority.

BBIBP-CorV is one of at least 10 coronavirus vaccine projects globally to have entered Phase III trials, four of which are led by Chinese scientists, according to the World Health Organization.

Sputnik V is now undergoing phase 3 clinical trials in Russian Federation.

Kirill Dmitriev, CEO of the RDIF, said: "We are pleased to collaborate with the Indian regulators and in addition to the Indian clinical trial data, we will provide safety and immunogenicity study from the Russian phase 3 clinical trial".

Victoria records 10 new coronavirus cases and seven further COVID-19 deaths
According to the state's health authorities, three new fatalities were reported which took the Victoria's death toll to 784. Andrews declared a state of disaster across Victoria on August 2, and imposed stage 4 lockdown measures in Melbourne.

Now two indigenously developed vaccine candidates for Covid-19, one by Bharat Biotech in collaboration with ICMR and another one by Zydus Cadila Ltd, are undergoing phase 2 of human clinical trials.

The phase 3 efficacy trials are expected to take longer as researchers have to wait for sets of volunteers to develop the coronavirus disease and demonstrate that the proportion falling ill in the recipients' group is significantly smaller than those in the non-recipients' group.

The authorities did not say how many in the city had been given the vaccine, which comes in two doses, administered up to 28 days apart and costing 400 yuan (S$81.50). Additionally, phase 3 clinical trial of the vaccine has commenced in the UAE last week, the release on Saturday said.

The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100 percent of participants developing antibodies to the new coronavirus with no serious side effects, news agency Reuters reported Lancet as saying.

In September, Dr Reddy's signed a partnership agreement with the Russian Direct Investment Fund (RDIF), which funded the development of the drug.